Surgery Partners, Inc.·4

Mar 9, 7:33 PM ET

Burkhalter Danielle 4

Research Summary

AI-generated summary

Updated

Surgery Partners (SGRY) CHRO Danielle Burkhalter Receives RSAs, Sells Shares

What Happened
Danielle Burkhalter, Chief Human Resources Officer at Surgery Partners (SGRY), was granted restricted stock awards (RSAs) on March 5, 2026, and sold shares on March 6, 2026 to satisfy tax withholding. Grants on March 5 totaled 43,230 RSAs: 17,717 shares @ $14.11 (value $249,987), 16,363 shares @ $14.11 (value $230,882), and 9,150 shares @ $14.11 (value $129,107) — combined value $609,976. On March 6 she sold 7,736 shares in an open-market/private-sale at a weighted average price of $13.60 for proceeds of $105,210; the sale was to cover tax withholding related to RSAs that vested on Feb 28 and Mar 2.

Key Details

  • Transaction types: A = Award/Grant (RSAs); S = Sale; F = tax withholding.
  • Grant date: March 5, 2026 — three RSA awards totaling 43,230 shares (total value $609,976 at $14.11 reported price).
  • Sale date: March 6, 2026 — 7,736 shares sold at a weighted average price of $13.60 for $105,210 (footnote says weighted avg; detailed per-price breakouts available on request).
  • Vesting: One RSA award vests in three equal annual installments starting on the 1st anniversary (F3); one vests on the 1st anniversary (F4); one vests on the 2nd anniversary (F5).
  • Reason for sale: Footnote F1 states shares were sold to satisfy the reporting person’s tax withholding obligations for RSAs that vested Feb 28 and Mar 2.
  • Shares owned after the reported transactions: not disclosed in the filing.
  • Filing/timeliness: Form 4 filed March 9, 2026 for transactions on March 5–6; filing is within the SEC’s two-business-day reporting window.

Context
The grants are restricted stock awards with multi-year vesting schedules (not immediate cash sales), so the awards represent deferred compensation rather than an immediate market buy signal. The sale was a routine tax-withholding disposition, which is common and does not necessarily indicate a view on the company’s prospects.